Imidazolidine derivative and use thereof
US5691335A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 28, 1996 |
| Grant date | Nov 25, 1997 |
| Priority date | — |
| Expiry date | Mar 28, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to an imidazolidine derivative represented by the following general formula (1): ##STR1## wherein A and B mean individually an aromatic hydrocarbon group which may be substituted by 1-3 substituents selected from halogen atoms, C.sub.1-4 alkyl groups, C.sub.1-4 alkoxy groups, C.sub.1-4 alkylenedioxy groups, a phenoxy group, a nitro group, a cyano group, a phenyl group, C.sub.2-5 alkanoylamino groups, a carboxyl group which may be esterified with a C.sub.1-4 alkyl or alkenyl group, carboxyalkyl groups which may be esterified with a C.sub.1-4 alkyl or alkenyl group, carboxyalkyloxy groups which may be esterified with a C.sub.1-4 alkyl or alkenyl group, N-alkylpiperazinylcarbonyl groups, N-alkylpiperazinylcarbonylalkyl groups, N-alkylpiperazinylcarbonylalkyloxy groups, and a morpholinocarbonyl group; X denotes a sulfonyl or carbonyl group; and Y stands for an oxygen or sulfur atom, a chymase inhibitor comprising the same as an active ingredient, and a medicine comprising the same as an active ingredient, typified by a prophylactic and therapeutic agent for a disease of the heart or circulatory system, which is caused by the abnormal acceleration of production of …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.